| PACKAGING TYPE: | 10x10 Blister (10 Strips In1 Box) |
| COMPOSITION: | Gliclazide 30mg+pioglitazone 15mg+metformin Hydrocloride 500mg |
| FORMULATION: | Tablet |
| Description: | GLYZIMAC TOTAL 30 Tablet is a triple-combination antidiabetic medication containing: Gliclazide 30mg – a sulfonylurea that stimulates insulin secretion from pancreatic beta cells. Pioglitazone 15mg – a thiazolidinedione that improves insulin sensitivity in peripheral tissues. Metformin Hydrochloride 500mg – a biguanide that reduces hepatic glucose production and enhances insulin utilization. This advanced combination is used for the management of Type 2 Diabetes Mellitus, especially in patients requiring intensive glycemic control. It provides comprehensive blood sugar management by targeting multiple pathways involved in glucose regulation. |
| Side Effects: | Common side effects: Nausea or gastrointestinal discomfort Weight gain (due to Pioglitazone) Headache Hypoglycemia Rare but serious side effects: Lactic acidosis (rare, due to Metformin) Fluid retention or edema Liver function abnormalities Severe hypoglycemia Allergic reactions (rash, swelling, difficulty breathing) |
| How to Use: | Take GLYZIMAC TOTAL 30 Tablet orally, usually once daily with meals or as prescribed. Swallow the tablet whole with water. Do not skip meals to avoid hypoglycemia. Maintain a healthy diet and regular exercise routine. Monitor blood glucose levels regularly. |
| Precaution: | Monitor for hypoglycemia symptoms (sweating, dizziness, confusion). Use cautiously in patients with heart failure (due to Pioglitazone). Avoid excessive alcohol consumption (risk of lactic acidosis). Use with caution in liver and kidney impairment. Inform your doctor about all medications to avoid interactions. Not recommended during pregnancy or breastfeeding without medical advice. |
| Product Benefits: | Provides triple-action blood glucose control. Helps reduce fasting and postprandial blood sugar levels. Improves insulin secretion and insulin sensitivity. Reduces risk of long-term diabetic complications. Suitable for patients not controlled with dua |
Frequently Asked Questions
It is used to manage Type 2 Diabetes Mellitus with better control using triple-drug therapy.
It is prescribed for patients who are not adequately controlled on single or dual antidiabetic therapy.
Yes, Pioglitazone in the combination may cause weight gain or fluid retention.










